U.S. markets closed
  • S&P Futures

    4,018.00
    +16.75 (+0.42%)
     
  • Dow Futures

    32,562.00
    +128.00 (+0.39%)
     
  • Nasdaq Futures

    12,927.75
    +37.50 (+0.29%)
     
  • Russell 2000 Futures

    1,760.00
    +12.30 (+0.70%)
     
  • Crude Oil

    69.69
    +0.43 (+0.62%)
     
  • Gold

    1,977.10
    -6.70 (-0.34%)
     
  • Silver

    23.31
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0768
    +0.0003 (+0.03%)
     
  • 10-Yr Bond

    3.3800
    -0.0260 (-0.76%)
     
  • Vix

    21.74
    -0.87 (-3.85%)
     
  • GBP/USD

    1.2234
    +0.0003 (+0.03%)
     
  • USD/JPY

    130.7560
    +0.0550 (+0.04%)
     
  • Bitcoin USD

    28,029.75
    +415.73 (+1.51%)
     
  • CMC Crypto 200

    610.54
    -7.85 (-1.27%)
     
  • FTSE 100

    7,405.45
    -94.15 (-1.26%)
     
  • Nikkei 225

    27,375.40
    -9.85 (-0.04%)
     

Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

BRIDGEWATER, N.J., January 31, 2023--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial 1 (844) 200-6205 (in the U.S.) or 1 (929) 526-1599 (international callers). The access code for the call is 477511.

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1 (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 942331.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005199/en/

Contacts

Anthony DiMeo
Head of Investor Relations
Anthony.DiMeo@amneal.com